ArticleHIV medicine2025
The association between HIV drug resistance testing, viral suppression and mortality in Ontario: a retrospective cohort study.
Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundDrug resistance compromises the effectiveness of antiretroviral therapy (ART). Resistance testing prior to initiating therapy is recommended in guidelines in many high-income countries, and it has been shown to improve outcomes after first-line ART regimen failure. There is limited evidence on its role in treatment-naïve individuals. We sought to investigate the association between resistance testing and viral suppression and mortality in people living with HIV initiating treatment in Ontario, Canada, where resistance testing became standard of care in 2014.
methodsWe conducted a retrospective cohort study from 2005 to 2018 using Ontario health administrative databases linked to the Ontario HIV Treatment Network (OHTN) Cohort Study (OCS). Eligible cohort participants were those who had complete data within the follow-up time range. We used logistic regression to compare the odds of viral suppression (<200 copies/mL, at 6-18 months) and death between people living with HIV who had a record of resistance testing prior to treatment and those who did not. We adjusted for age, sex, year ART was started, race, sexual orientation, level of education, income, adherence, anchor drug, immigration status, injection drug use, viral load and baseline CD4 count.
resultsOf 1806 eligible participants, 716 were analysed for death, of which 3.7% had died at the end of follow-up. Six hundred and ninety-nine (699) were analysed for viral suppression, of which 94.6% achieved viral suppression. Resistance testing prior to ART initiation had no significant association with viral suppression (odds ratio [OR] 1.13; 95% confidence interval [CI] 0.58-2.22) or death (OR 1.06 95% CI 0.49-2.28) in the covariate-adjusted models. Viral suppression was more likely in older age and in people who started treatment with non-nucleoside reverse transcriptase inhibitors compared to protease inhibitors, and in people with a higher baseline CD4 count. The odds of death were higher in individuals who were older.
conclusionResistance testing was not associated with viral suppression and death. Outcomes were associated with clinical and demographic factors, notably regimen, baseline CD4 count and age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.